{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:05:47Z","timestamp":1792044347683,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017559","name":"Recordati Rare Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The majority of prolactinomas are treated with dopamine agonists (DA) with excellent response, however DA-resistance occurs in 10% of prolactinomas. Somatostatin (SST) receptors have been increasingly studied in prolactinomas. There are five SST receptor subtypes and a significant number of prolactinomas show expression of SST\n                    <jats:sub>5<\/jats:sub>\n                    and SST\n                    <jats:sub>1<\/jats:sub>\n                    mRNA. The somatostatin analog (SSA) pasireotide, which has 40-fold greater binding affinity to SST\n                    <jats:sub>5<\/jats:sub>\n                    compared to first-generation SSAs, shows promising results in case reports of DA-resistant prolactinomas. This two-center retrospective cohort study investigated the expression patterns of dopamine 2 (D2R), SST\n                    <jats:sub>2<\/jats:sub>\n                    and SST\n                    <jats:sub>5<\/jats:sub>\n                    receptors in surgical specimen of 34 patients with prolactinomas, 22 of which were DA-resistant. In vitro effects of cabergoline, octreotide and pasireotide on prolactin production was also examined in cultured prolactinoma cells. Receptor expression was scored using the immunoreactivity score (IRS). 31\/34(91%) patients used DA preoperatively; 22\/34(64.7%) were DA-resistant. Receptor expression in the cases was 97.1% for D2R, 70.6% for SST\n                    <jats:sub>5<\/jats:sub>\n                    and 41.2% for SST\n                    <jats:sub>2<\/jats:sub>\n                    . In the majority of SST\n                    <jats:sub>2<\/jats:sub>\n                    positive cases SST\n                    <jats:sub>2<\/jats:sub>\n                    expression was very low. In in vitro studies comparing the effects of octreotide, pasireotide, and cabergoline on prolactin secretion, octreotide was the least potent drug and cabergoline was the most potent. SST\n                    <jats:sub>5<\/jats:sub>\n                    and D2R expression was highest in prolactinomas showing the highest response to pasireotide and cabergoline in vitro (median D2R IRS 1.0 vs 8.0 for &lt;\u200950% vs.\u2009&gt;\u200950% inhibition by cabergoline and median SST\n                    <jats:sub>5<\/jats:sub>\n                    IRS 3.5 avs. 12.0 for &lt;\u200950% vs.\u2009&gt;\u200950% inhibition by pasireotide). In a subgroup, pasireotide inhibited prolactin secretion with comparable potency to cabergoline. Targeting SST\n                    <jats:sub>5<\/jats:sub>\n                    with pasireotide may be a potential treatment modality for further clinical investigation in the treatment of a subset of DA resistant or intolerant prolactinomas.\n                  <\/jats:p>","DOI":"10.1007\/s11102-025-01580-7","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T19:03:22Z","timestamp":1762196602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Somatostatin 5 receptor expression in prolactinomas: Is there a role for Pasireotide in the management of prolactinomas?"],"prefix":"10.1007","volume":"28","author":[{"given":"Nidhi","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samara","family":"Skwiersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadime","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"van Koetsveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian J. C. M. M.","family":"Neggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zagzag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo J.","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"1580_CR1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad174","author":"RS Auriemma","year":"2023","unstructured":"Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R (2023) Approach to the patient with prolactinoma. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgad174","journal-title":"J Clin Endocrinol Metab"},{"key":"1580_CR2","doi-asserted-by":"publisher","unstructured":"Ciccarelli A, Daly AF, Beckers A (2005) The epidemiology of prolactinomas, (in eng), Pituitary, vol. 8, no. 1, pp. 3\u20136. https:\/\/doi.org\/10.1007\/s11102-005-5079-0","DOI":"10.1007\/s11102-005-5079-0"},{"issue":"11","key":"1580_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/jcm11113070","volume":"11","author":"H Szmygin","year":"2022","unstructured":"Szmygin H, Szydelko J, Matyjaszek-Matuszek B (2022) Dopamine Agonist-Resistant Microprolactinoma-Mechanisms, predictors and management: A case report and literature review. J Clin Med 11(11):29. https:\/\/doi.org\/10.3390\/jcm11113070","journal-title":"J Clin Med"},{"key":"1580_CR4","doi-asserted-by":"publisher","unstructured":"Stumpf MAM et al (2023) How to manage intolerance to dopamine agonist in patients with prolactinoma, Pituitary, vol. 26, no. 2, pp. 187\u2013196, Apr https:\/\/doi.org\/10.1007\/s11102-023-01313-8","DOI":"10.1007\/s11102-023-01313-8"},{"key":"1580_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00886-5","author":"S Petersenn","year":"2023","unstructured":"Petersenn S et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"1580_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2023.102883","volume":"54","author":"I Shimon","year":"2023","unstructured":"Shimon I (2023) Prolactinomas resistant to dopamine agonists: pathophysiology and treatment. Arch Med Res 102883. https:\/\/doi.org\/10.1016\/j.arcmed.2023.102883","journal-title":"Arch Med Res"},{"key":"1580_CR7","doi-asserted-by":"publisher","first-page":"791633","DOI":"10.3389\/fendo.2021.791633","volume":"12","author":"C Pivonello","year":"2021","unstructured":"Pivonello C et al (2021) Resistance to dopamine agonists in pituitary tumors: molecular mechanisms. Front Endocrinol (Lausanne) 12:791633. https:\/\/doi.org\/10.3389\/fendo.2021.791633","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"1580_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1530\/EJE-07-0806","volume":"158","author":"A Fusco","year":"2008","unstructured":"Fusco A et al (2008) Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol 158(5):595\u2013603. https:\/\/doi.org\/10.1530\/EJE-07-0806","journal-title":"Eur J Endocrinol"},{"key":"1580_CR9","doi-asserted-by":"publisher","unstructured":"Jaquet P et al (Sep 1999) Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas, (in eng). J Clin Endocrinol Metab 84(9):3268\u20133276. https:\/\/doi.org\/10.1210\/jcem.84.9.5962","DOI":"10.1210\/jcem.84.9.5962"},{"key":"1580_CR10","doi-asserted-by":"publisher","unstructured":"Souteiro P, Karavitaki N (2020) Dopamine agonist resistant prolactinomas: any alternative medical treatment? (in eng), Pituitary, vol. 23, no. 1, pp. 27\u201337, Feb https:\/\/doi.org\/10.1007\/s11102-019-00987-3","DOI":"10.1007\/s11102-019-00987-3"},{"key":"1580_CR11","doi-asserted-by":"publisher","unstructured":"Lasolle H, Vasiljevic A, Borson-Chazot F, Raverot G (2019) Pasireotide: A potential therapeutic alternative for resistant prolactinoma, (in eng), Ann Endocrinol (Paris), vol. 80, no. 2, pp. 84\u201388, Apr https:\/\/doi.org\/10.1016\/j.ando.2018.07.013","DOI":"10.1016\/j.ando.2018.07.013"},{"key":"1580_CR12","doi-asserted-by":"publisher","unstructured":"Campana C et al (Sep 1 2022) Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study. Eur J Endocrinol 187(3):399\u2013411. https:\/\/doi.org\/10.1530\/EJE-22-0339","DOI":"10.1530\/EJE-22-0339"},{"issue":"4","key":"1580_CR13","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1210\/jc.2003-031344","volume":"89","author":"LJ Hofland","year":"2004","unstructured":"Hofland LJ et al (Apr2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89(4):1577\u20131585. https:\/\/doi.org\/10.1210\/jc.2003-031344","journal-title":"J Clin Endocrinol Metab"},{"key":"1580_CR14","doi-asserted-by":"publisher","unstructured":"Ioachimescu AG, Fleseriu M, Hoffman AR, Vaughan Iii TB, Katznelson L (Jan 1 2019) Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol 180(1):31\u201340. https:\/\/doi.org\/10.1530\/EJE-18-0682","DOI":"10.1530\/EJE-18-0682"},{"key":"1580_CR15","doi-asserted-by":"publisher","unstructured":"Oh MC, Aghi MK (2011) Dopamine agonist-resistant prolactinomas, (in eng), J Neurosurg, vol. 114, no. 5, pp. 1369-79, May https:\/\/doi.org\/10.3171\/2010.11.Jns101369","DOI":"10.3171\/2010.11.Jns101369"},{"issue":"3","key":"1580_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1210\/jcem-69-3-500","volume":"69","author":"I Pellegrini","year":"1989","unstructured":"Pellegrini I et al (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69(3):500\u2013509. https:\/\/doi.org\/10.1210\/jcem-69-3-500","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1580_CR17","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1210\/clinem\/dgad174","volume":"108","author":"RS Auriemma","year":"2023","unstructured":"Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R (2023) Approach to the patient with prolactinoma. J Clin Endocrinol Metab 108(9):2400\u20132423. https:\/\/doi.org\/10.1210\/clinem\/dgad174","journal-title":"J Clin Endocrinol Metab"},{"key":"1580_CR18","doi-asserted-by":"publisher","unstructured":"Shimazu S et al (2012) Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels, Eur J Endocrinol, vol. 166, no. 3, pp. 383\u2009\u2013\u200990, Mar https:\/\/doi.org\/10.1530\/EJE-11-0656","DOI":"10.1530\/EJE-11-0656"},{"issue":"no. 7","key":"1580_CR19","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1210\/clinem\/dgad020","volume":"108","author":"AR de Castro Moreira","year":"2023","unstructured":"de Castro Moreira AR et al (2023) PRL-R variants are not only associated with prolactinomas but also with dopamine agonist resistance. J Clin Endocrinol Metab 108(7):e450\u2013e457. https:\/\/doi.org\/10.1210\/clinem\/dgad020","journal-title":"J Clin Endocrinol Metab"},{"key":"1580_CR20","doi-asserted-by":"publisher","unstructured":"Raverot G, Vasiljevic A, Jouanneau E, Lasolle H (2019) Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors, (in eng), Eur J Endocrinol, vol. 181, no. 2, pp. C1-c3, Aug https:\/\/doi.org\/10.1530\/eje-19-0359","DOI":"10.1530\/eje-19-0359"},{"key":"1580_CR21","doi-asserted-by":"publisher","unstructured":"Thodou E, Kontogeorgos G, Theodossiou D, Pateraki M (Mar 2006) Mapping of somatostatin receptor types in GH or\/and PRL producing pituitary adenomas, (in eng). J Clin Pathol 59(3):274\u2013279. https:\/\/doi.org\/10.1136\/jcp.2005.026914","DOI":"10.1136\/jcp.2005.026914"},{"key":"1580_CR22","doi-asserted-by":"publisher","unstructured":"Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S (Nov 1 1997) Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors, (in eng). J Clin Invest 100(9):2386\u20132392. https:\/\/doi.org\/10.1172\/jci119779","DOI":"10.1172\/jci119779"},{"key":"1580_CR23","doi-asserted-by":"publisher","unstructured":"Coopmans EC et al (2019) Excellent response to Pasireotide therapy in an aggressive and dopamine-resistant prolactinoma, (in English). Eur J Endocrinol 181 2, pp. K21-K27, 01 Aug. 2019. https:\/\/doi.org\/10.1530\/eje-19-0279","DOI":"10.1530\/eje-19-0279"},{"key":"1580_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.935759","volume":"13","author":"A Mondin","year":"2022","unstructured":"Mondin A et al (2022) Pasireotide-induced shrinkage in GH and ACTH secreting pituitary adenoma: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 13:935759. https:\/\/doi.org\/10.3389\/fendo.2022.935759","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1580_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000472563","volume":"106","author":"M Korner","year":"2018","unstructured":"Korner M, Waser B, Christ E, Beck J, Reubi JC (2018) A critical evaluation of sst3 and sst5 immunohistochemistry in human pituitary adenomas. Neuroendocrinology 106(2):116\u2013127. https:\/\/doi.org\/10.1159\/000472563","journal-title":"Neuroendocrinology"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01580-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01580-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01580-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:47:08Z","timestamp":1765961228000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01580-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1580"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01580-7","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}